Strides Pharma Science subsidiary receives USFDA approval for generic Pregabalin capsules, a medication for nerve pain. The product is bio-equivalent to Lyrica capsules and has a market size of USD 248 million in the US.
Photograph: Yves Herman/Reuters
New Delhi, Jan 25 (PTI) Strides Pharma Science on Thursday said its subsidiary has received approval from the US health regulator for a generic medication for nerve pain.
Singapore-based Strides Pharma Global Pte has received approval for Pregabalin capsules from the US Food & Drug Administration (USFDA), the drug maker said in a regulatory filing.
The company's product is bio-equivalent and therapeutically equivalent to the reference listed drug -- Lyrica capsules -- used in the treatment of fibromyalgia.
As per IQVIA data, Pregabalin capsules have a market size of USD 248 million in the US market.
Shares of Strides Pharma Science on Thursday ended 2.27 per cent up at Rs 685.75 apiece on the BSE.
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback